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ABSTRACT OF THESIS 
 
 
TRENDS AND PATTERNS IN USE OF MEDICATIONS FOR OPIOID USE 
DISORDER IN A COMMERCIALLY INSURED POPULATION IN THE U.S. 
 
Opioid use disorder (OUD) and opioid overdose are pervasive public health 
problems in the U.S.  Medications for opioid use disorder (MOUD) have been shown 
effective to reduce OUD morbidity and mortality.  Two distinct approaches to MOUD are 
currently used: agonist therapy (methadone or buprenorphine) or antagonist therapy 
(naltrexone).  Limited information is available about the patterns of use, adherence to 
therapy, and characteristics of those who use agonist vs. antagonist therapy.  The objective 
of this study is to assess recent trends in MOUD, adherence in use of MOUD, and the 
characteristics of those who use agonist vs. antagonist therapy in a nationally representative 
population of commercially insured patients in the U.S.    
This retrospective descriptive study utilized data from Truven Marketscan 
Commercial Claims and Encounters database from years 2011 to 2016.  All individuals 
aged 18 years and older who have a diagnosis of OUD and utilize MOUD at any point 
during the study period were included.  Demographic characteristics of interest included 
age, gender, geographic region, and type of insurance coverage.  Clinical characteristics of 
interest included diagnosis of OUD and type of MOUD used, including extended – release 
naltrexone for injection, oral naltrexone, buprenorphine in combination with naloxone, and 
buprenorphine alone.  Descriptive analyses were employed to understand utilization 
patterns and trends over time and proportion of days covered was used to measure 
adherence.   Frequency and percentage are presented for categorical variables.  Adherence 
of MOUD will be estimated by measuring proportion of days covered.  As this study uses 
de-identified commercial health claims data, it has been determined as not human subjects 
research by the University of Kentucky’s Office of Research Integrity.   
Agonist therapy with buprenorphine or buprenorphine/naloxone was the most 
common treatment, representing 75.7% of those receiving treatment. Between 2011 and 
2016, the percentage of individuals receiving treatment with partial agonist therapy 
decreased 16.5% to 9.2%, respectively.  Meanwhile, the percentage of individuals 
receiving treatment with antagonist treatment increased from 0.1% in 2011 to 0.3% in 
2016.  In the analysis of proportion of days covered, all MOUD reported a decrease at both 
180 and 365 days.  In the commercial population, younger female patients were more likely 
to be treated with injectable naltrexone.  Specifically, in the North Central geographic 
region, commercial adult patients were more likely to be treated with buprenorphine 
monotherapy.  
Overall, this study found a decrease in use of agonist therapy from 2011 through 
2016, with an increase in use of antagonist therapy in the same time period.  However, the 
increase in use of antagonist therapy does not fully account for the decrease in use of 
agonist therapy, suggesting that since 2011 many patients with OUD still remain untreated.  
  
     
 
All MOUD types were analyzed and saw a decrease in proportion of days covered, as a 
measure of adherence, from 2011 to 2016 putting patients at an increased risk for relapse, 
further complications, emergency visits, and hospitalizations.  More information is needed 
about characteristics of patients who not only seek out treatment for OUD, but also 
maintain their treatment overtime.   
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CHAPTER 1.  INTRODUCTION 
PAIN 
 Pain is defined as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage.1  It is considered a public health problem that effects 
approximately 100 million American adults and contributes significantly to morbidity, 
mortality, and disability.2  Pain impacts a patient’s ability to work, engage in social 
activities, and perform basic activities of daily living.  Annually, it costs society 
approximately $560 billion to $635 billion in direct health care costs and loss of 
productivity.2  This represents a higher annual cost than heart disease, cancer, and diabetes, 
and does not even include the cost of patients in nursing homes, military personnel, 
children under 18 years old, or correction inmates.2   
Common medications for treatment of pain include acetaminophen, nonsteroidal 
anti-inflammatory drugs, topical agents like lidocaine, capsaicin, and diclofenac, and 
opioids.  Patients with acute, chronic, and cancer related pain can significantly benefit from 
the use of prescription opioids including morphine, codeine, oxycodone, hydrocodone, and 
fentanyl for their analgesic effect.3,4,5  Opioids work by binding to the mu, kappa, and delta 
receptors in the central nervous system causing inhibition of the ascending pain pathway 
altering the perception of and response to pain.6  Along with their analgesic effects, opioids 
target the brain’s reward system by flooding the circuit with dopamine.  This 
overstimulation produces a euphoric effect that is a major cause of improper use, diversion, 
dependence, and addiction.7  
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Addiction is defined as a, “primary, chronic and relapsing brain disease 
characterized by an individual pathologically pursuing reward and or relief by substance 
use and other behaviors.”8 Continued misuse of prescription opioids may result in 
addiction and development of opioid use disorder.   
OPIOID USE DISORDER  
Opioid Use Disorder (OUD) and opioid overdose are pervasive public health 
problems in the United States.  OUD is treatable chronic brain disease defined as a pattern 
of repeated opioid use that causes change in neural structure and significant impairment or 
distress.9  The diagnosis of OUD is based on specific criteria over a 12-month period 
including unsuccessful efforts to cut down or control use, use resulting in social problems, 
failure to fulfill obligations at work, school, or home, and other criteria.10  Anyone who 
uses opioids for the management of pain is at risk for developing OUD and having an 
opioid overdose.  
The history of opioid overdose deaths has been classified by the Centers for Disease 
Control and Prevention (CDC) in three distinct waves.  The first wave beginning in the 
early 1990s with increased rates of opioid prescribing and death involving prescription 
opioids.  The second wave beginning in 2010, with opioid overdose deaths involving 
heroin.  The third wave beginning in 2013 with overdose deaths rising from illicitly 
manufactured fentanyl and carfentanil.  During the three waves from the 1990s to 2017, 
approximately 400,000 people died from an overdose involving a prescription or illicit 
opioid.11   
Today, approximately 130 Americans die daily from a prescription, illicit, or 
combination opioid overdose.11 Of the adolescent population aged 12 to 17 years old, 3.6% 
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report misusing opioids.  This percentage doubles among older adolescents and young 
adults aged 18 to 25 years old.  This opioid misuse costs $78.5 billion annually in direct 
and indirect costs including the cost of healthcare, lost productivity, addiction treatment, 
and criminal justice involvement.12 In response, the U.S. Department of Health and Human 
Services (HHS) declared the opioid crisis a public health emergency.  HHS outlined a five-
point strategy to combat the opioid crisis, one of which is to improve access to treatment 
and recovery services.13 Effective treatment of OUD can reduce the risk of opioid overdose 
and help affected persons attain a healthier life.   
MEDICATIONS FOR OPIOID USE DISORDER 
Medications for opioid use disorder (MOUD) have been shown to be effective at 
reducing OUD morbidity and mortality.  They are used in combination with behavioral 
therapy and are intended to normalize brain structure and function.9 MOUD can help 
decrease opioid use, increase social functioning, increase retention in treatment, and 
decrease deaths from overdose.  They are highly effective across all population subgroups 
including adolescents, older persons, pregnant women, individuals with co-occurring 
disorders, and all racial, sex and gender, and socioeconomic groups.9 Two distinct 
approaches to MOUD are currently used: agonist therapy with methadone or 
buprenorphine, or antagonist therapy with naltrexone.7  
Methadone, a full opioid receptor agonist, has been used for OUD treatment for the 
past 40 years.14  It works by binding to the opioid receptors in the central nervous system 
(CNS), causing inhibition of the ascending pain pathways, and altering the perception of 
and response to pain.15  It eliminates withdrawal symptoms, blocks the euphoric effects of 
opioids, and relieves drug cravings.15   
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Methadone is offered in an oral tablet, oral solution, and an injectable form and is 
taken once daily by patients in a licensed outpatient treatment program under the 
supervision of a physician.15  The dose of methadone for detoxification is highly 
individualized taking into account the patient’s severity of pain, patient response, prior 
analgesic treatment experiences, and risk factors for addiction.  An initial starting dose is 
typically 20 to 30 mg when a patient shows signs of withdrawal and no signs of sedation 
or intoxication. The dose is then titrated to the patient’s maintenance dose, typically 80 to 
120 mg daily.16  The maintenance dose prevents opioid withdrawal symptoms for 24 hours, 
inhibits cravings, and blocks the euphoric effect of opioids.16  The length of time in 
methadone treatment for OUD varies from person to person, but according to the National 
Institute on Drug Abuse, the minimum length of treatment should be 12 months.14    More 
recently, the National Academies of Sciences, Engineering, and Medicine reported that 
long-term retention on MOUD is associated with improved outcomes and lower chances 
of relapse and overdose.9  
Similar to other prescription and illicit opioids, methadone also has high potential 
for abuse and dependence.15  Along with its addictive properties, patients taking 
methadone may also experience serious adverse effects including respiratory depression, 
somnolence, swelling of face, lips, tongue or throat, hives, rash, chest pain, confusion, 
generalized CNS depression, or death.17  Due to these properties, when methadone is used 
for OUD treatment, it can only be dispensed through a treatment program certified by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) where  clinical 
response and behavior can be monitored.15,18  Federal restrictions make it difficult to access 
patient data for those using methadone for treatment of OUD.15,18 
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Buprenorphine, another medication for treatment of OUD, is a partial opioid 
agonist and has been available since October 2002.19 It exhibits high affinity binding to the 
mu opioid receptor in the CNS, displaying mu agonist activity.  It also possesses weak 
kappa antagonist activity.  As its analgesic effect plateaus at higher doses, it then starts to 
behave like an antagonist.20 Similarly to methadone, buprenorphine is prescribed in 
combination with behavioral therapy such as counseling and participation in social support 
programs.19  It is the first medication used for treatment of OUD that is permitted to be 
prescribed in outpatient physicians’ offices and dispensed in community pharmacies, 
significantly increasing treatment access.19  
Buprenorphine is effective for treatment for OUD because of its’ ability to reduce 
cravings and withdrawal symptoms.19 It is offered in several dosage forms including a 
buccal film, a sublingual tablet, a subcutaneous implant, and as an injection.  It is either 
taken daily in an outpatient treatment program or prescribed to a patient to take daily at 
home by a provider who has received a waiver to prescribe buprenorphine.21  Through the 
waiver process, practitioners, including physicians and more recently advanced registered 
nurse practitioners and physician assistants when allowed by state law, receive an “X” 
license from the DEA that specifically allows providers with extra training in addiction 
treatment to prescribe buprenorphine.21   
Treatment with buprenorphine occurs in three phases. The first stage, the induction 
phase, takes place in a qualified physician or other practitioner’s office or certified opioid 
treatment program.  An initial dose of buprenorphine 2 to 4 mg daily is administered when 
the patient with OUD has abstained from using opioids for at least 12 to 24 hours and is in 
early withdrawal.19  This phase has the potential to put the patient into withdrawal if they 
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still have opioids in their blood stream.  The stabilization phase, or second phase of 
buprenorphine treatment, begins when the patient has greatly reduced their use of opioids, 
no longer has cravings, and experiences few side effects.  The dose of buprenorphine can 
be adjusted during this phase. Similarly, to methadone, there is variability between patients 
in the effective dose of buprenorphine. A typical dose may range from 4 mg to 16 mg 
daily.20 The maintenance phase, or final phase, occurs when the patient is stable on a dose 
of buprenorphine. The length of the maintenance phase varies for each individual and 
could be indefinite.19 Long-term retention on buprenorphine is associated with improved 
outcomes and lower chances of relapse and overdose.9  
Buprenorphine exhibits addictive analgesic effects, and therefore can be misused 
and abused by patients.  Naloxone is added in combination with buprenorphine to decrease 
the likelihood of diversion and misuse of the drug.19  It works as a pure opioid antagonist 
that competes and displaces opioids on their receptor sites.22  If the medication is misused 
by patients and injected instead of used as a sublingual tablet or film, naloxone will block 
the euphoric effects of buprenorphine and can precipitate withdrawal in a patient dependent 
on opioids.19   
One special population to note are pregnant patients.  Buprenorphine monotherapy, 
specifically, can be used for treatment of OUD during pregnancy.  Utilizing buprenorphine 
prevents opioid withdrawal symptoms, reduces risk of relapse, improves adherence to 
prenatal care, and reduces the risk of obstetric complications.  Compared to methadone for 
treatment of OUD during pregnancy, buprenorphine has fewer drug interactions, can be 
treated as an outpatient outside of an opioid treatment program, does not require as many 
dose adjustments, and carries a smaller risk for neonatal abstinence syndrome.  Typically, 
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buprenorphine monotherapy is recommended over the combination drug product with 
naloxone to avoid any potential prenatal exposure to naloxone, but recent studies 
evaluating the combination product have found no adverse effects.23  
Naltrexone, differing from buprenorphine and methadone, is a non-addictive, 
competitive opioid antagonist, showing highest affinity for the mu receptors.24,25 It 
immediately precipitates withdrawal in patients using opioids and treats OUD by blocking 
any opioid from the ability to exhibit its’ rewarding euphoric effect.24  While the oral 
version has been available since 1984, for the treatment of addiction to drugs such as 
heroin, morphine and oxycodone, the intramuscular, long acting form was approved in 
2010 for use in OUD.  The injectable dosage form created a new administrative option for 
patients needing help with adherence and for those who did not want to take an oral 
medication daily.24    
Naltrexone is initiated seven to ten days following last use of opioids.24  A naloxone 
or naltrexone challenge test and urine toxicology may be performed to ensure the patients 
has completed withdrawal from opioids before the long-acting injection is administered.25  
The tablet form is dosed at 25mg to 50 mg once daily, but some patients may require doses 
up to 100 mg daily.25 The long-acting injection is dosed as 380 mg intramuscularly into 
the gluteal muscle once monthly by physician or other health care professional.25 Similar 
to methadone and buprenorphine, treatment with naltrexone should be accompanied by 
behavioral and counseling support.24  Differing from methadone and buprenorphine, this 
treatment modality represents the first therapy for OUD that has no abuse and diversion 
potential.  Common adverse effects of naltrexone that patients should be aware of include 
upset stomach, vomiting, diarrhea, headache, nervousness, sleep disturbances, joint pain, 
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and muscle pain.  Other adverse effects can include liver injury, injection site reactions, 
and allergic pneumonia.25   
UTILIZATION OF MEDICATIONS FOR OPIOID USE DISORDER 
It is important to understand who receives medications, which medications they 
receive, and how it varies by patient characteristics.  This information is important to 
contribute to the expansion of OUD treatment services, a national priority in the United 
States.13  Recent data from the National Survey on Drug Use and Health indicated that only 
22.5% of individuals with OUD receive treatment.26  A greater understanding is needed of 
those individuals who receive treatment to be able to better treat other OUD patients with 
similar characteristics moving forward.  Studies assessing the utilization of MOUD in the 
veteran, youth, and adult populations are summarized below. 
1.4.1 Use in the Veteran Population 
 In study by Manhapra and colleagues, characteristics of veterans utilizing 
buprenorphine and methadone for OUD nationally were analyzed from January 1, 2012 to 
December 31, 2012.  The objective of the study was to gain a better understanding of the 
varying characteristics of veterans in three different OUD treatment groups.  The three 
groups identified were those who received buprenorphine only (n=5,670, 39.28%), those 
who received methadone only (n=6,252, 43.31%), and those who received both 
buprenorphine and methadone in the same year (n=2,513, 17.41%).  The three groups were 
compared using bivariable analyses of sociodemographic characteristics, diagnostic 
characteristics, health service use, and psychotropic medication fills.  Logistic regression 
models were used to identify variables independently associated with receiving 
buprenorphine compared to methadone, methadone compared with using buprenorphine 
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and methadone in the same year, and buprenorphine compared with using buprenorphine 
and methadone in the same year.  From the bivariable comparisons, the researchers found 
that veterans who received buprenorphine only were younger by nearly a decade, more 
likely to reside in a rural area, less likely to receive a VA pension, and more likely to have 
served in Iraq or Afghanistan compared to the other two groups.  They found that the 
methadone only group was comprised of 40% African Americans, representing three times 
the number of African Americans than the other two groups. Also, veterans with more 
comorbidities were more likely to receive methadone compared to the other two groups.  
From the multivariable analysis, the researchers found that those who were younger by 
nearly a decade (OR 0.67; 95% CI 0.64 – 0.70), living in an urban setting (OR 0.26; 95% 
CI 0.25 – 0.33), and African American race (OR 0.39; 95% CI 0.35 - 0.43), were associated 
with lower odds of receiving buprenorphine compared to methadone.  Researchers also 
looked at medical comorbidities and other psychiatric comorbidities and medications, but 
they did not identify significant difference between the three groups.27   
Overall in this study of veteran patients with OUD, receiving buprenorphine or 
methadone was associated with demographic characteristics rather than medical 
comorbidities or psychiatric comorbidities.  A limitation identified within this study is that 
only full agonist and partial agonist MOUD were analyzed, and no information was 
provided about antagonist therapy.  Also, only the veteran population was analyzed in this 
study, and so it may not be generalizable to other populations.27   
 Another study about veterans, published by Shiner and colleagues, researched 
utilization of MOUD in those with OUD and post-traumatic stress disorder (PTSD) from 
2004 to 2013.  Of the 731,520 veterans with PTSD, 19,998 (2.7%) veterans were found to 
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have a comorbid OUD diagnosis.  From the 19,998 veterans with a diagnosis of OUD, 
5,913 (29.6%) received a MOUD in the year following their initial PTSD diagnosis.   
MOUD included in the study were buprenorphine, methadone, and naltrexone.  The 
researchers found the comorbid OUD diagnosis increased overtime from 2.5% in 2004 to 
3.4% in 2013 and that MOUD utilization increased from 22.6% in 2004 to 35.1% in 2013. 
More specifically, buprenorphine utilization increased from 2.0% to 22.7%, methadone 
utilization decreased from 19.3% to 12.7% and naltrexone utilization increased from 2.8% 
to 8.6%.  They further classified veterans who were younger, living in a rural area, married, 
and Caucasian as more likely to be treated with buprenorphine for OUD compared to those 
who were older, living in an urban setting, unmarried, and part of a minority as more likely 
to be treated with methadone. Veterans who received naltrexone were typically married, 
Caucasian women with a comorbid alcohol use disorder diagnosis.28 This study builds on 
the previous veterans study by including all three MOUD and clearly outlines specific 
characteristics of veterans who were more likely to receive one type of MOUD compared 
to another.   
1.4.2 Use in the Youth Population 
In a retrospective cohort study by Hadland and colleagues from January 1, 2001 to 
June 30, 2014, trends in receiving buprenorphine or naltrexone among youth aged 13 to 25 
years old were analyzed.29  Risk for OUD typically begins in the youth population, with 
7.8% of high school seniors reporting nonmedical use of prescription opioids. Of the 
20,822 youth diagnosed with OUD included in the study, 5,580 (26.8%) were dispensed a 
medication for OUD within 6 months of their diagnosis. Of the 5,580 youth dispensed a 
medication, 89.2% (n=4,976) were prescribed buprenorphine while 10.8% (n=604) were 
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prescribed naltrexone.  MOUD utilization increased more than 10 times from 3.0% in 2002 
to 31.8% in 2009, and then decreased to 27.5% in 2014 in youth.  From the multivariable 
analysis, researchers found that the odds of receiving buprenorphine compared to 
naltrexone increased from 2002 to 2010 (OR, 1.31 per year; 95% CI, 1.22 – 1.39), but the 
odds of receiving naltrexone relative to buprenorphine increased from 2010 to 2014 (OR, 
1.17 per year; 95% CI, 1.09 – 1.25).  Overall, youth were less likely to receive a MOUD if 
they were younger, female, and black or Hispanic, and low-middle neighborhood poverty 
level.  When youth did receive a MOUD, they were less likely to receive buprenorphine 
than naltrexone if they were younger or female.  Youth were more likely to receive 
buprenorphine if they were from a non-metropolitan area, lower middle to low educational 
level neighborhood, a high poverty level neighborhood, or from the Midwest. Naltrexone 
was more commonly dispensed to younger individuals, females, those living in 
metropolitan area, those with higher education level neighborhoods, and lower poverty 
level neighborhoods.29 This study outlines specific characteristics of youth who were more 
likely to receive buprenorphine or naltrexone for treatment of OUD.  Additional 
information is needed to determine if similar trends in buprenorphine and naltrexone 
utilization are observed in the adult population.   
1.4.3 Use in the Adult Population 
In a retrospective cohort study by Morgan and colleagues from 2010 to 2014, 
prescribing patterns MOUD were analyzed in a commercially insured population.30 
Specific medications investigated were injectable naltrexone, oral naltrexone, sublingual 
or oral-mucosal buprenorphine in combination with naloxone, sublingual buprenorphine, 
and transdermal buprenorphine.  Although transdermal buprenorphine is not FDA 
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approved for opioid use disorder, it is approved for chronic pain.  Researchers chose to 
include this dosage form of buprenorphine in their study because they limited the data to 
only patients with OUD and it appears some patients were utilizing transdermal 
buprenorphine for treatment.  The prevalence of OUD and proportion of diagnosed patient 
months on OUD medication in the database were calculated each year.  Unadjusted 
descriptive statistics were utilized to compare characteristics of patients diagnosed with 
OUD who received and did not receive MOUD.   
From 2010 to 2014, individuals diagnosed with OUD in this population grew from 
0.12% to 0.48%, while the proportion of diagnosed patient months on medication 
decreased from 25% in 2010 to 16% in 2014.  The population of patients with OUD was 
growing, while the number of patients being treated was decreasing.  Patients were more 
likely to receive a MOUD if they were male, younger, and had an additional substance use 
disorder. Patients with the same three characteristics were also more likely to be prescribed 
injectable naltrexone over the other medications.  Researchers found that after 30 days of 
therapy, 52% of patients treated with injectable naltrexone, 70% of individuals treated with 
oral naltrexone, 31% of individuals treated with sublingual buprenorphine/naloxone, 58% 
of patients treated with sublingual buprenorphine alone, and 51% patients treated with 
transdermal buprenorphine discontinued treatment.  Further, a Cox proportional hazard 
regression model showed that patients using injectable naltrexone, oral naltrexone, 
sublingual buprenorphine, and transdermal buprenorphine were more likely to discontinue 
therapy beginning > 30 days after MOUD initiation (HR = 2.17, 2.54, 1.15, 2.21, 95% CI 
2.04 – 2.30, 2.45 – 2.64, 1.10 – 1.19, 2.11 – 2.33) compared with sublingual buprenorphine 
in combination with naloxone.30   
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 In another study utilizing the adult population, Ronquest and colleagues analyzed 
the relationship between buprenorphine adherence and relapse, health care utilization, and 
costs in privately and publicly insured patients with OUD.31  Patients with OUD prescribed 
buprenorphine between 2008 and 2014 were included in the study and followed for 12 
months after their earliest outpatient pharmacy claim for buprenorphine.  Adherence to 
buprenorphine was measured by proportion of days covered (PDC).  PDC was calculated 
by the sum of day supply in the study period divided by days in the follow – up period (365 
days).  The researchers defined a PDC of ≥ 0.80 as adherent.  Descriptive and adjusted 
analyses compared relapse prevalence, utilization, and costs of adherent patients to non-
adherent patients.  Of those in the commercial sample (n=16,085), 37.1% were found to be 
adherent, while 41.3% of those in the Medicaid sample (n= 5,688) were found to be 
adherent. Total costs (pharmacy and medical) for adherent patients in the Commercial 
sample ($17,519) were significantly lower than non-adherent patients ($20,294 - $24,431), 
while in the Medicaid sample, total costs were not significantly different between the 
groups.  In conclusion, researchers found that the buprenorphine adherence in the 12 
months following the earliest outpatient claim was associated with reduced odds of relapse 
and reduced total healthcare costs.  Non-adherent patients were found to have more 
hospitalizations and emergency room visits.31 This study included new information in 
comparison to previous studies on adherence to buprenorphine as treatment for OUD.  It is 
limited because it only analyzed one modality of MOUD, buprenorphine, and no others.  
 From the above studies, we have learned about some of the characteristics in 
veterans, youth, and adults that show who is more likely to receive one type of MOUD 
compared to another.  The studies reported information on the utilization of MOUD over 
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time, but only have data that goes through 2014.  More information is needed on the 
changes in MOUD utilization in more recent years. Only one study provides information 
on adherence, through PDC, to buprenorphine following OUD diagnosis and the first 
outpatient pharmacy claim.  Additional information is needed on the adherence to all 
MOUDs.  Overall, this information will further help clinicians determine the best treatment 
option for their patients based on the patient’s characteristics and which treatment option 
has the best adherence for treatment success overtime.   
 
1.5    PURPOSE AND OBJECTIVES 
Relatively limited information is available about the patterns of use, adherence, and 
the characteristics of those who use agonist versus antagonist therapy in the adult, 
commercially insured population.  Thus, the primary objective of this descriptive study to 
assess trends in medications used for OUD in a population of commercially insured patients 
in the United States from 2011 - 2016.  Further, the secondary objectives are to describe 
the demographic characteristics of those who use agonist vs. antagonist therapy, to measure 
adherence to MOUD through proportion of days covered at 6 and 12 months following 
initiation of therapy and to measure the odds of receiving injectable naltrexone in this 
patient population compared to other forms of MOUD, including buprenorphine 
monotherapy, buprenorphine in combination with naloxone, and oral naltrexone.  
Although this is a descriptive study, we hypothesize that from 2011 through 2016, 
there will be an increase in the utilization of injectable naltrexone compared to other types 
of MOUD.  In a study by Jackson and colleagues, effectiveness and cost–effectiveness of 
extended release injectable naltrexone were compared to methadone and buprenorphine 
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maintenance treatment in adult males ages 18 to 65 years old over 6 months. The results 
show that injectable naltrexone is more costly that methadone or buprenorphine but is more 
effective at discouraging opioid use while on treatment.  Results suggest that injectable 
naltrexone can be cost effective if health payers are willing to pay $72 per opioid free day 
gained (equivalent to treating three patients with methadone for one day), because it 
discourages opioid use preventing more complications in the future.32   
  
CHAPTER 2. METHODS 
DATA SOURCE 
Data were obtained from individuals enrolled in the Truven Marketscan 
Commercial Claims Database between January 1, 2011 and December 31, 2016.  The 
database contains individual level health care claims data.  Information is available from 
almost 115 million commercially insured patients, their spouses, and dependents from a 
broad geographic area across the United States.  The database provides information on 
medical, dental, and prescription claims at the patient level, laboratory results, health risk 
assessments, and hospital discharges.33  All study data were de-identified and anonymous, 
so the study does not meet the federal definition of “human subjects research” and thus was 
exempt from IRB review by the University of Kentucky’s Office of Research Integrity.  
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COHORT 
All individuals aged 18 years and older with an International Classification of Disease 
Code (ICD) – 9 or ICD – 10 diagnosis of OUD (Appendix 3) were eligible to be included 
in the cohort. The codes were not validated for accuracy in identifying patients with OUD.  
Medications approved by the FDA for OUD were identified by generic product identifier 
codes and classified as agonist (buprenorphine, buprenorphine/naloxone) or antagonist 
(oral naltrexone and injectable naltrexone) using national drug codes.  See Appendix 1.  
Patients were included in the study if were at least 18 years and old and a had a prescription 
claim for agonist and or antagonist therapy.  All individuals under the age of 18 and without 
a diagnosis of OUD were excluded from the study.  Other patients excluded were those 
who had a prescription claim for agonist or antagonist therapy in the 6 months prior to their 
diagnosis with OUD to ensure they were receiving this medication for OUD and not for 
other indications like pain or alcohol use disorder.  See Figure 1.    
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Figure 1. Inclusion and Exclusion Diagram for Patients with OUD 
488,485 with OUD
436,920 meeting inclusion 
criteria 
80,482 treated with agonist 
and/or antagonist therapy
356,438 untreated
Excluded: 7,702 patients 
who were < 18 years old
Excluded: 43,863 who had 
claims for agonist and 
antagonist therapy 6 
months prior to the OUD 
diagnosis 
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Figure 2: Timeline of Study Period  
 
2.3    STUDY DESIGN AND STATISTICAL ANALYSIS 
 
 This retrospective, descriptive study used administrative claims data from Truven 
Marketscan Commercial Claims Database between January 1, 2011 and December 31, 
2016.  Demographic characteristics of interest included age, gender, geographic region, 
and type of insurance coverage.  Clinical characteristics of interest included diagnosis of 
OUD and type of MOUD used, including extended-release naltrexone for injection, oral 
naltrexone, buprenorphine in combination with naloxone, and buprenorphine 
monotherapy.  Buprenorphine monotherapy dosage forms included the buccal film, 
sublingual tablet, and injection.  Buprenorphine in combination with naloxone dosage 
forms included the sublingual film, sublingual tablet, and buccal film.  Dosage forms 
excluded in this study were bulk powders, methylnaltrexone bromide injection, 
No agonist 
or antagonit 
treatment (6 
month 
period prior 
to 
enrollment)
OUD 
Diagnosis, 
Date of 
Enrollme-nt 
(starting 
January 1, 
2011)
Date of 
first 
prescripti
on claim 
for 
MOUD
Measurem
ent of PDC 
at 180 
days 
following 
first 
MOUD 
prescriptio
n
Measure
ment of 
PDC at 
365 days 
followin
g first 
MOUD 
prescript
ion
End of 
study 
period 
(Dec-
ember 
31, 
2016) 
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methylnaltrexone bromide tablet, naltrexone-bupropion extended release tablet, morphine-
naltrexone capsule, and the buprenorphine transdermal patch because they are not used for 
treatment of opioid use disorder.  Methadone was also not included in this study because 
there are no pharmacy claims for it since it is administered in outpatient treatment programs 
and not dispensed in pharmacies.   
Descriptive analyses, including frequency and percentage for all categorical 
demographic variables, were utilized to understand patterns and trends of MOUD over time   
Demographic variables assessed included sex, age, geographic region, and insurance plan.  
Associations between patient characteristics and type of treatment received, including 
those untreated, were assessed via likelihood ratio chi-square test.  Adherence was 
measured using the PDC for each continuously enrolled individual MOUD at 6 months 
(180 days) and 12 months (365 days) following treatment initiation.  The total number of 
days covered by an MOUD were calculated from the days of supply information on 
pharmacy claims regardless of gaps in therapy.  PDC was calculated as sum of days covered 
in the study period divided by study period days (180 days or 365 days).22 See tables 3 and 
4 and appendix 2.   Multinomial logistic regression was used to estimate the odds of 
receiving each type of OUD medication relative to the odds of receiving injectable 
naltrexone predicted by age (reference group = 18 to 26 years old), gender (reference group 
= male), geographic region (reference group = South), and insurance plan (reference group 
= Preferred Provider Organization). All statistical analyses were conducted using SAS 
version 9.4.   
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3.0     RESULTS 
 
 
3.1      DESCRIPTIVE CHARACTERISTICS   
 
Among the 436,920 patients identified as having OUD and meeting inclusion 
criteria between 2011 and 2016, 80,482 (18.4%) were treated with a medication while 
356,438 (81.6%) remained untreated during the study period.  Of the treated patients, 
agonist therapy was the most common treatment, representing 84.0% of those receiving 
treatment, antagonist therapy was utilized for treatment of 10.3% of patients, and a 
combination of agonist and antagonist therapy was utilized in 5.7% of patients.  Those 
utilizing combination therapy, did not utilize both therapies simultaneously, but within the 
same year.  Males represented the majority of patients, > 50.0%, in each treated group and 
the untreated group.  The age group 18 to 26 years old represented the largest number of 
patients treated for OUD in each medication group (buprenorphine monotherapy 38.5%, 
buprenorphine/naloxone 37.1%, oral naltrexone 46.4%, injectable naltrexone 54.0%).  
However, in the untreated group the largest age group represented were those older than 
50 years old (27.4%).  The South represents the geographic region and Preferred Provider 
Organization (PPO) represents the commercial insurance type with the most patients both 
treated and untreated for OUD.  All demographic variables showed evidence of a 
statistically significant (p <0.0001) association with the type of treatment received, 
including those who were untreated.  See Table 1. 
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Table 1: Descriptive Characteristics of Unique Individuals with OUD, 2011 – 2016 
 
 Total Agonist 
n = 67,499 
 
Total Antagonist 
n = 8,363 
 
  
Parameter Buprenorphine 
Monotherapy 
n=6,554 
Buprenorphine/ 
Naloxone 
n=66,945 
Oral 
Naltrexone 
n=7,313 
Injectable 
Naltrexone 
n=1,050 
Agonist & 
Antagonist 
Combination 
n = 4,620 
 
Untreated 
n = 356,438 
 
Sex 
Female 3,010 
(45.93%) 
20,785 
(34.10%) 
3,100 
(42.39%) 
372 
(35.43%) 
1,698 
(36.75%) 
168,470 (47.26%) 
Male 3,544 
(54.07%) 
40,160 
(65.90%) 
4,213 
(57.61%) 
678 
(64.57%) 
2,922 
(63.35%) 
187,968 (52.75%) 
Age 
18 – 26 2,526 
(38.54%) 
22,597 
(37.08%) 
3,391 
(46.37%) 
567 
(54.00%) 
3,202 
(69.31%) 
82,931 (23.27%) 
27 – 35 1,599 
(24.40%) 
16,328 
(26.79%) 
1,213 
(16.59%) 
178 
(16.95%) 
657 
(14.22%) 
53,984 (15.15%) 
36 – 50 1,550 
(23.65%) 
15,137 
(24.84%) 
1,691 
(23.12) 
196 
(18.67%) 
559 
(12.10%) 
97,823 (27.44%) 
50 + 879 
(13.41%) 
6,878 
(11.29%) 
1,005 
(13.74%) 
109 
(10.38%) 
200 
(4.33%) 
121,700 (34.14%) 
Geographic Region 
Northeast1 1,183 
(18.05%) 
14,951 
(24.53%) 
1992 
(27.24%) 
301 
(28.67%) 
1,422 
(30.78%) 
77,538 
(21.75%) 
 
  
   
2
2
 
Table 1 (continued): Descriptive Characteristics of Unique Individuals with OUD, 2011 – 2016 
 Total Agonist 
n = 67,499 
 
Total Antagonist 
n = 8,363 
 
  
Parameter Buprenorphine 
Monotherapy 
n=6,554 
Buprenorphine/ 
Naloxone 
n=66,945 
Oral 
Naltrexone 
n=7,313 
Injectable 
Naltrexone 
n=1,050 
Agonist & 
Antagonist 
Combination 
n = 4,620 
 
 
Untreated 
n = 356,438 
 
South3 2,670 
(40.74%) 
24,023 
(39.42%) 
2,578 
(35.25%) 
396 
(37.71%) 
1,300 
(28.14%) 
141,427 
(39.68%) 
West4 1,702 
(25.97%) 
8,826  
(14.48%) 
1,192 
(16.30%)  
173 
(16.48%) 
842 
(18.23%) 
68,473 (19.21%)  
Insurance* 
EPO5 67 
 (1.02%) 
729  
(1.20%) 
89 
(1.22%) 
15 
(1.43%) 
41 
 (0.89%) 
7,008 (1.97%) 
HMO6 465  
(7.09%) 
5,810 
(9.53%) 
741 
(10.13%) 
75 
(7.14%) 
427 
 (9.24%) 
36,628 (10.28%) 
POS7 549 
 (8.38%) 
4,677 
(7.67%) 
509 
(6.96%) 
74 
(7.05%) 
396 
(8.57%) 
25,093 (7.04%) 
PPO8 4,247 
(64.80%) 
37,931 
(62.24%) 
4,424 
(60.50%)  
688 
(65.52%) 
2,880 
(62.34%) 
214,183 (60.09%) 
Other 909  
(13.87%) 
7,491 
(12.29%) 
1,246 
(17.04%) 
157 
(14.95%) 
687 
(14.87%) 
46,748 (13.12%) 
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Table 1 (continued): Descriptive Characteristics of Unique Individuals with OUD, 2011 – 
2016 
 
1Northeast: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, 
New Jersey, New York, Pennsylvania 
2 North Central: Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, 
Missouri, Nebraska, North Dakota, South Dakota 
3 South: Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South 
Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, 
Louisiana, Oklahoma, Texas 
4 West: Arizona, Colorado, Idaho, New Mexico, Utah, Nevada, Wyoming, Alaska, 
California, Hawaii, Oregon, Washington 
5EPO: Exclusive Provider Organization 
6HMO: Health Maintenance Organization 
7PPO: Point of Service 
8PPO: Preferred Provider Organization 
 
 
 
3.2      TRENDS IN MOUD UTILIZATION FROM 2011 THROUGH 2016  
 
Of the 436,920 patients meeting inclusion criteria from 2011 through 2016, trends in 
utilization of each MOUD are reported in Table 2.  The rate of patients utilizing buprenorphine 
monotherapy from 2011 through 2016 increased from 1.2% to 1.4%.  In the buprenorphine-
naloxone group, the rate of patients utilizing the MOUD from 2011 to 2016 decreased from 
16.5% to 9.2%.  In the injectable naltrexone group, the rate of patient utilizing the MOUD 
increased from 0.1% to 0.3%.  Also, the rate of oral naltrexone utilization increased from 1.1% 
in 2011 to 2.0% in 2016.  The rate of untreated patients decreased from 79.9% in 2011 to 
86.6% in 2016. See Table 2, Figure 2, and Figure 3.  
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Table 2: Patients with OUD by Year and Type of Treatment Including those Untreated  
 Year of Index OUD Diagnosis 
Therapy 2011 2012 2013 2014 2015 2016 
Buprenorphine 
monotherapy 
1,058 
(1.2%) 
1,182 
(1.5%) 
1,028 
(1.5%) 
1,280 
(1.5%) 
1,145 
(2.0%) 
861 
(1.4%) 
Buprenorphine-
Naloxone 
14,215 
(16.5%) 
13,249 
(17.0%) 
10,416 
(15.5%) 
10,492 
(12.2%) 
6,875 
(11.9%) 
5,698 
(9.2%) 
 
Injectable 
Naltrexone 
94  
(0.1%) 
163  
(0.2%) 
180  
(0.3%) 
189  
(0.2%) 
229  
(0.4%) 
195 
(0.3%) 
 
Oral Naltrexone 
931 
(1.1%) 
1,159 
(1.5%) 
1,101 
(1.6%) 
1,464 
(1.7%) 
1,386 
(2.4%) 
1,269 
(2.0%) 
Buprenorphine and 
Naltrexone1 
994 
(1.2%) 
1,005 
(1.3%) 
901 
(1.3%) 
813 
(0.9%) 
596 
(1.0%) 
311 
(0.5%) 
 
Untreated 
68,730 
(79.9%) 
61,270 
(78.5%) 
53,370 
(79.7%) 
71,909 
(83.5%) 
47,391 
(82.2%) 
53,778 
(86.6%) 
 
Total 
86,022 
(100.0%) 
78,028 
(100.0%) 
66,996 
(100.0%) 
86,147 
(100.0%) 
57,622 
(100.0%) 
62,112 
(100.0%) 
1 Filled both buprenorphine and naltrexone prescriptions during the follow-up period 
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Figure 3: Percent of Patients with OUD, Treated and Untreated, from 2011 through 2016 
 
 
 
 
 
 
Figure 4: Percent Treated OUD Patients by Year and Type of Treatment 
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3.3      PROPORTION OF DAYS COVERED BY MOUD TYPE AT 6 MONTHS 
 
Among the 6,554 patients in the buprenorphine monotherapy group, the PDC 
decreased from 0.54 in 2011 to 0.41 in 2016 within the first 6 months following the first 
prescription claim.  Of the 66,945 patients in the buprenorphine naloxone combination 
group, the PDC increased from 0.59 in 2011 to 0.60 in 2014, and then subsequently 
decreased to 0.52 in 2016.  Of the 7,313 patients included in the oral naltrexone group, 
there was an overall decrease in PDC from 0.32 in 2011 to 0.29 in 2016.  Of the 1,050 
patients in the injectable naltrexone group, the PDC decreased from 0.53 in 2011 to 0.37 
in 2016.  Of the 5,038 patients in the combination group of agonist and antagonist therapy, 
the PDC decreased from 0.47 in 2011 to 0.38 in 2016.  See Table 3.   
Table 3: Proportion of Days Covered at 6 months (180 Days) for those Receiving MOUD 
by Medication Type, 2011 – 2016 
 Buprenorphine Monotherapy Buprenorphine/Naloxone 
Year Day 
Covered in 
6 Months 
Days 
Treated in 6 
Months 
PDC Days Covered 
in 6 Months 
Days 
Treated in 6 
Months 
PDC 
2011 86,241 156,780 0.54 1,294,269 2,207,340 0.59 
2012 91,502 192,420 0.47 1,328,194 2,320,920 0.57 
2013 84,289 169,560 0.49 1,123,340 1,892,700 0.59 
2014 103,394 224,460 0.46 1,181,686 1,970,100 0.60 
2015 105,533 206,280 0.49 775,716 1,307,340 0.59 
2016 94,105 230,220 0.41 666,265 1,271,700 0.52 
 
 Injectable Naltrexone Oral Naltrexone 
Year Day 
Covered in 
6 Months 
Days 
Treated in 
6 Months 
PDC Days Covered 
in 6 Months 
Days Treated 
in 6 Months 
PDC 
2011 5,254 9,900 0.53 42,566 132,660 0.32 
2012 8,428 21,960 0.38 55,462 184,320 0.30 
2013 11,256 30,420 0.37 54,962 181,800 0.30 
2014 14,321 34,380 0.41 78,173 253,980 0.30 
2015 16,720 42,480 0.39 80,217 248,940 0.32 
2016 18,512 49,860 0.37 91,078 314,640 0.29  
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Table 3 (continued): Proportion of Days Covered at 6 months (180 Days) for those 
Receiving MOUD by Medication Type, 2011 – 2016 
 Agonist & Antagonist Therapy 
Year Days 
Covered 
in 6 
months 
Days 
Treated 
in 6 
Months 
PDC 
2011 63,050 132,300 0.47 
2012 79,887 167,400 0.47 
2013 76,694 167,760 0.45 
2014 66,075 154,440 0.42 
2015 53,040 128,160 0.41 
2016 31,756 81,540 0.38 
 
3.4      PROPORTION OF DAYS COVERED BY MOUD TYPE AT 12 MONTHS 
 
Among the 6,554 patients in the buprenorphine monotherapy group, the PDC 
decreased from 0.45 in 2011 to 0.26 in 2016 within the first 12 months following the first 
prescription claim.  Of the 66,945 patients in the buprenorphine naloxone combination 
group, the PDC decreased from 0.47 in 2011 to 0.35 in 2016.  The 7,313 patients included 
in the oral naltrexone group, saw an overall decrease in PDC from 0.19 in 2011 to 0.15 in 
2016.  Of the 1,050 patients in the injectable naltrexone group, the PDC decreased from 
0.34 in 2011 to 0.20 in 2016.  Of the 5,038 patients in the combination group of agonist 
and antagonist therapy, the PDC decreased from 0.39 in 2011 to 0.25 in 2016.  See Table 
4. 
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Table 4: Proportion of Days Covered at 12 Months (365 Days) for those Receiving 
MOUD Treatment by Medication Type, 2011 – 2016 
 
 Buprenorphine Monotherapy Buprenorphine/Naloxone 
Year Days 
Covered in 
12 Months 
Days 
Treated 
in 12 
Months 
PDC Days Covered in 
12 Months 
 
 
Days 
Treated in 
12 Months 
PDC 
2011 143,325 317,915 0.45 2,103,540 4,475,995 0.47 
2012 138,661 390,185 0.35 2,064,500 4,706,310 0.43 
2013 137,375 343,830 0.39 1,822,672 3,837,975 0.47 
2014 167,316 455,155 0.36 1,848,472 3,994,925 0.46 
2015 165,847 418,290 0.39 1,278,397 2,650,995 0.48 
2016 123,397 466,835 0.26 901,092 2,578,725 0.35 
 
 Injectable Naltrexone Oral Naltrexone 
Year Days 
Covered in 
12 Months 
Days 
Treated 
in 12 
Months 
PDC Days Covered in 
12 Months 
Days Treated 
in 12 Months 
PDC 
2011 7,156 20,075 0.35 52,191 269,005 0.19 
2012 10,237 44,530 0.23 65,148 373,760 0.17 
2013 13,750 61,685 0.22 65,924 368,650 0.18 
2014 17,601 69,715 0.25 92,721 515,015 0.18 
2015 22,681 86,140 0.26 98,457 504,795 0.19 
2016 20,999 101,105 0.21 99,255 638,020 0.15 
 
 Agonist & Antagonist Therapy 
Year Days 
Covered 
in 12 
months 
Days 
Treated 
in 12 
Months 
PDC 
2011 103,186 268,275 0.39 
2012 128,871 339,450 0.37 
2013 123,661 340,180 0.36 
2014 103,827 313,170 0.33 
2015 86,625 259,880 0.33 
2016 42,440 165,345 0.25 
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3.5      PREDICTORS OF RECEIVING AN MOUD TYPE 
 
When determining the odds of receiving a type of MOUD, injectable naltrexone 
was used as the reference group as well as age 18 to 26 years old, male sex, PPO insurance 
plan, and the south geographic region.  All individuals greater than 26 years old had higher 
odds of receiving buprenorphine monotherapy, buprenorphine naloxone, and oral 
naltrexone, versus injectable naltrexone, than did individuals aged 18 to 26 years old.  
Females had greater odds of receiving buprenorphine monotherapy and oral naltrexone, 
versus injectable naltrexone, than did males. Patients with health maintenance organization 
insurance had higher odds of receiving buprenorphine in combination with naloxone and 
oral naltrexone, versus injectable naltrexone, than patients with preferred provider 
organization insurance.  Patients in the north central and northeast region were less likely 
to receive buprenorphine monotherapy versus injectable naltrexone, than did patients in 
the south geographic region.  Patients living in the west geographic region, were more 
likely to receive buprenorphine monotherapy versus injectable naltrexone than patients in 
the south geographic region. See Table 5. 
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Table 5: Odds of an Individual Receiving a Type of MOUD Therapy, 2011- 2016 
 
 
 Type of MOUD therapy (Injectable Naltrexone – 
Reference Group)  
 
 
Independent variables 
 
Buprenorphine 
monotherapy 
OR (95% CI) 
 
Buprenorphine-
naloxone 
OR (95% CI) 
 
Oral naltrexone 
OR (95% CI) 
Age    
18 – 26 (Reference Group)    
27-35  2.03 (1.68, 2.45) 2.32 (1.95, 2.77) 1.18 (0.98,1.45) 
36-50 1.74 (1.45, 2.08) 1.93 (1.63,2.28) 1.44 (1.21,1.72) 
> 50 1.71 (1.37,2.13) 1.54 (1.25,1.89) 1.44 (1.15,1.79) 
    
Sex    
Male (Reference Group)    
Female 1.48 (1.29,1.70) 0.92 (0.81, 1.05) 1.33 (1.15,1.52) 
    
Insurance    
 PPO (Reference Group)    
EPO 0.84 (0.47,1.45) 1.06 (0.63,1.78) 0.98 (0.56,1.70) 
HMO 0.94 (0.72,1.22) 1.49 (1.17,1.91) 1.53 (1.18,1.97) 
POS 1.28 (0.99,1.65) 1.19 (0.9641.53) 1.09 (0.84,1.42) 
Other 0.98 (0.81,1.19) 0.88 (0.74,1.05) 1.21 (1.00,1.47) 
    
Geographic Region    
 South (Reference Group)    
North central 0.80 (0.65,0.97) 1.22 (1.02, 1.47) 1.26 (1.04,1.54) 
Northeast 0.56 (0.47,0.66) 0.75 (0.64, 0.88) 0.97 (0.82,1.14) 
West 1.58 (1.30,1.93) 0.90 (0.75,1.08) 1.06 (0.87,1.28) 
 
 
4.0     DISCUSSION  
 
4.1     GENERAL 
 
 Opioid use disorder is a growing epidemic within the United States.  The analysis 
demonstrates that the use of evidence- based medication therapies has not kept pace with 
increase in OUD diagnosis and many patients are left untreated.  In this retrospective, 
descriptive study, I found that 81.6% of patients remain untreated.  Only about one- fifth 
or 18.4% of individuals with a diagnosis of OUD received medication treatment which is 
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approximately in line with recent data from the National Survey on Drug Use and Health 
indicating that in 2016, only 22.5% of individuals with OUD received treatment.26 Agonist 
therapy with buprenorphine or buprenorphine/naloxone was the most common treatment, 
representing 75.7% of those receiving treatment. Between 2011 and 2016, the percentage 
of individuals receiving treatment with partial agonist therapy decreased 16.5% to 9.2%, 
respectively.  Meanwhile, the percentage of individuals receiving treatment with injectable 
antagonist treatment increased from 0.1% in 2011 to 0.3% in 2016.  Extended-release 
injectable naltrexone was FDA approved for OUD in 2010 and may account for this 
increase in use, but the increase in use of antagonist therapy is not great enough to offset 
the decline in agonist therapy treatment.   
Adherence to MOUD was measured by proportion of days covered at 180 days and 
365 days following the first pharmacy claim for a MOUD.  In the first analysis at 180 days, 
all MOUD reported a decrease in proportion of days covered from 2011to 2016.  More 
specifically, the injectable naltrexone group showed the largest decrease from 0.53 PDC in 
2011 to 0.37 PDC in 2016 likely putting them at increased risk of relapse compared to other 
MOUD within the first 6 months.  In the second analysis at 365 days, all MOUD reported 
a decreased in PDC from 2011 to 2016.  The buprenorphine monotherapy group decreased 
from 0.45 PDC in 2011 to 0.26 PDC in 2016, putting these patients at increased risk of 
relapse compared to other MOUD within in the first 12 months.   
All demographic variables showed evidence of a statistically significant (p 
<0.0001) association with the type of treatment received, including those who were 
untreated.  Age, sex, geographic region, and insurance plan type all contribute towards the 
type of MOUD treatment a patient receives or if they remain untreated.    
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In the multivariate analysis study by Manhapra, veterans were less like to receive 
buprenorphine if they were in a younger age group, living in an urban area, and African 
American race.  Although I cannot compare our results directly to this study, I found a 
difference in the commercially insured patients, younger patients were more likely to 
receive injectable naltrexone. In the other study of veterans by Shiner and colleagues, an 
increase was found in use buprenorphine for treatment of OUD from 2.0% in 2004 to 
22.7% in 2013 and an increase in naltrexone from 2.8% in 2004 to 8.6% in 2013.  In the 
commercial population from this study, overall, there was a decrease in use of 
buprenorphine and buprenorphine naloxone from 2011 to 2013 and a continued decrease 
in use until 2016, but a similar increase in use of naltrexone from 2011 to 2013 with 
continued increased until 2016.  Veterans were more likely to be treated with 
buprenorphine if they were younger, living in a rural area, married, and Caucasian.  Based 
on the variables that studied in the commercial population, I found that younger patients 
were more likely to be treated with injectable naltrexone.  Veterans were more like to be 
treated with naltrexone if they were married, Caucasian, women, and had comorbid alcohol 
use disorder.  Of the variables studied in the commercial population, I found similar results 
that females were more likely to be treated with injectable naltrexone.   
In the multivariate analysis by Hadland and colleagues from January 1, 2001 to 
June 30, 2014, youth were at an increased odd of receiving buprenorphine from 2002 to 
2010 but switched to an increased odd of receiving naltrexone from 2010 to 2014.  
Comparing this to the commercial adult population, an increase in utilization of both 
injectable and oral naltrexone was observed from 2011 through 2014, with continued 
increase in utilization to 2016.  Extended-release injectable naltrexone was FDA approved 
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for OUD in 2010 and may account for this increase in use.  Youth were more likely to 
receive buprenorphine if they were from a non-metropolitan area, lower middle class, high 
poverty, and from the Midwest.  Although this cannot be directly compared to my study, I 
did find that commercial adult patients were more likely to be treated with buprenorphine 
monotherapy in the North Central geographic region which is equivalent to the Midwest 
region.  Youth treated with naltrexone for OUD were younger, female, living in a metro 
area, and had a high education level. Similar results were found in the commercial adult 
population where younger females were more likely to be treated with injectable 
naltrexone.  
 
4.2     LIMITATIONS 
 
Results from this commercially insured population may not be representative of the 
OUD population at large. Individuals with OUD receiving agonist therapy with methadone 
at certified opioid treatment programs (OTPs) are not included in administrative claims 
data. Other patients that are excluded from the results are those who pay cash for their 
medication. The data for study relies on the provider assessment, diagnosis, and properly 
coding ICD – 9 and ICD – 10 codes for OUD.  No formal research assessment is included 
to confirm proper diagnosis of OUD.  The proportion of days covered calculation is based 
on prescription fills and reported day supply, but no information was available to determine 
if the patient actually took their medication for OUD.  Limited demographic characteristics 
were analyzed.  Others to consider include race, education level, income level, other 
comorbid substance use disorder, and mental illness history.  Finally, this study was limited 
to individuals with commercial insurance coverage and results may not be generalizable to 
patients with other types of coverage or with no insurance coverage.   
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5.0     CONCLUSION 
 
Overall, this study found a decrease in use of agonist therapy from 2011 through 
2016, with an increase in use of antagonist therapy in the same time period.  This trend is 
in line with the hypothesis that the utilization of injectable naltrexone would increase from 
2011 to 2016.  However, the increase in use of antagonist therapy does not fully account 
for the decrease in use of agonist therapy, suggesting that since 2011 many patients with 
OUD still remain untreated. This study adds the current literature published on veterans, 
youth, and adults.  All MOUD types were analyzed and saw a decrease in proportion of 
days covered, as a measure of adherence, from 2011 to 2016 putting patients at an increased 
risk for relapse, further complications, emergency visits, and hospitalizations.  Age, sex, 
type of insurance plan, and geographic region contribute toward which MOUD a patient 
receives, but more patient characteristics need to be analyzed in the future.  More 
information is needed about characteristics of patients who not only seek out treatment for 
OUD, but also maintain their treatment overtime.   
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APPENDICES 
APPENDIX A. NATIONAL DRUG CODES (NDC) AND FREQUENCY OF CLAIMS 
FOR MOUD 
Buprenorphine Monotherapy 
NDC Number Frequency 
00054017613 18832 
00054017713 106003 
00093537856 2078 
00093537956 5710 
00228315303 7188 
00228315603 1940 
00378092393 1794 
00378092493 7506 
12496075701 64 
12496075705 14 
12496127802 238 
12496131002 1016 
21695051510 6 
42023017905 3 
50383092493 7541 
50383093093 30412 
55390010010 3 
63481016160 205 
63481020760 310 
63481034860 262 
63481051960 82 
63481068560 80 
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63481082060 44 
63481095260 77 
68308020830 178 
 
Buprenorphine/Naloxone 
NDC Number Frequency 
00054018813 8176 
00054018913 41290 
00093572056 915 
00093572156 7631 
00228315403 10724 
00228316473 2104 
00228315503 55949 
00228315573 10845 
00406192303 1 
00406192403 11 
12496120201 353 
12496120203 134520 
12496120401 58 
12496120403 27025 
12496120801 2906 
12496120803 1115833 
12496121201 29 
12496121203 13877 
12496128302 40309 
12496130602 224206 
16590066630 2 
42291017430 133 
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42291017530 768 
43063018430 12 
50383028793 691 
50383029493 91 
52959030430 1 
52959074930 1 
54123011430 102 
54123091430 8449 
54123092930 460 
54123095730 46568 
54123098630 1651 
54569573900 8 
54569639900 6 
54868570700 1 
54868570701 1 
54868575000 1 
55700014730 1 
59385001201 8 
59385001230 342 
59385001401 36 
59385001430 3040 
59385001601 15 
59385001630 594 
60429058630 31 
60429058730 86 
65162041503 85365 
65162041603 14166 
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Injectable Naltrexone 
NDC Number Frequency 
63459030042 4 
65757030001 15736 
 
Oral Naltrexone 
NDC Number Frequency 
00185003901 130 
00185003930 27 
00406117001 3387 
00406117003 7651 
0055509201 9462 
00555090202 1386 
16729008101 983 
16729008110 10076 
42291063230 1 
473305032683 1405 
47335032688 1735 
51224020630 1063 
51224020650 1182 
51285027501 6 
52152010530 2 
6808409121 3 
68094085362 1 
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APPENDIX B.  PROPORTION OF DAYS COVERED (PDC) CALCULATION 
PDC = 
COVERED DAYS IN THE STUDY PERIOD
DAYS IN THE STUDY PERIOD (180 OR 365 DAYS)
 
 
APPENDIX C. INTERNATIONAL CLASSIFICATION OF DISEASE CODES (ICD – 9 
AND ICD – 10) TO IDENTIFY OPIOID USE DISORDER  
ICD code Version Label 
30400 ICD - 9 Opioid Type Dependence 
Unspecific Use 
30401 ICD – 9 Opioid Dependence 
Continuous 
30402 ICD – 9 Opioid Dependence 
Episodic 
30403 ICD - 9 Opioid Type Dependence 
Remiss 
F1110 ICD – 10 Opioid abuse, 
uncomplicated 
F11120 ICD – 10 Opioid abuse with 
intoxication 
F11121 ICD – 10 Opioid abuse with 
intoxication delirium 
F11122 ICD – 10 Opioid abuse with 
intoxication with 
perceptual disturbance 
F11129 ICD – 10 Opioid abuse with 
intoxication, unspecified 
F1114 ICD – 10 Opioid abuse with opioid – 
induced mood disorder 
F11150 ICD – 10 Opioid abuse with opioid 
induced psychotic disorder 
with delusions 
F11151 ICD - 10 Opioid abuse with opioid – 
induced psychotic disorder 
with hallucinations 
F11159 ICD – 10 Opioid abuse with opioid 
induced psychotic disorder, 
unspecified  
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F11181 ICD – 10 Opioid abuse with opioid-
induced sexual dysfunction 
F11182 ICD – 10 Opioid abuse with opioid – 
induced sleep disorder 
F11188 ICD – 9  Opioid abuse with opioid – 
induced disorder 
F1119 ICD – 10 Opioid abuse with 
unspecified opioid – 
induced disorder 
F1120 ICD – 10 Opioid dependence, 
uncomplicated 
F1121 ICD – 10 Opioid dependence, in 
remission 
F112220 ICD – 10 Opioid dependence with 
intoxication, 
uncomplicated 
F11221 ICD – 10 Opioid dependence with 
intoxication delirium  
F11222 ICD – 10 Opioid dependence with 
intoxication with 
perceptual disturbance 
F11229 ICD – 10 Opioid dependence with 
intoxication, unspecified 
F1123 ICD – 10 Opioid dependence with 
withdrawal 
F1124 ICD – 10 Opioid dependence with 
opioid-induced mood 
disorder 
F11250 ICD – 10 Opioid dependence with 
opioid-induced psychotic 
disorder with delusions 
F112151 ICD – 10 Opioid dependence with 
opioid-induced psychotic 
disorder with 
hallucinations 
F11259 ICD – 10 Opioid dependence with 
opioid-induced psychotic 
disorder, unspecified 
F11281 ICD – 10 Opioid dependence with 
opioid-induced sexual 
dysfunction 
F11282 ICD – 10 Opioid dependence with 
opioid-induced sleep 
disorder 
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F11288 ICD – 10 Opioid dependence with 
other opioid-induced 
disorder 
F1129 ICD – 10 Opioid dependence with 
unspecified opioid-induced 
disorder 
F1190 ICD – 10 Opioid use, unspecified, 
uncomplicated 
F11920 ICD – 10 Opioid use, unspecified 
with intoxication, 
uncomplicated 
F11921 ICD – 10 Opioid use, unspecified 
with intoxication delirium 
F11922 ICD – 10 Opioid use, unspecified 
with intoxication with 
perceptual disturbance 
F11929 ICD – 10 Opioid use, unspecified 
with intoxication, 
unspecified 
F1193 ICD – 10 Opioid use, unspecified 
with withdrawal 
F1194 ICD – 10 Opioid use, unspecified 
with opioid-induced mood 
disorder 
F11950 ICD – 10 Opioid use, unspecified 
with opioid-induced 
psychotic disorder with 
delusions 
F11951 ICD – 10 Opioid use, unspecified 
with opioid-induced 
psychotic disorder with 
hallucinations 
F11959 ICD – 10 Opioid use, unspecified 
with opioid-induced 
psychotic disorder, 
unspecified 
F11981 ICD – 10 Opioid use, unspecified 
with opioid-induced sleep 
disorder 
F11988 ICD – 10 Opioid use, unspecified 
with other opioid-induced 
disorder 
F1199 ICD – 10 Opioid use, unspecified 
with unspecified opioid-
induced disorder 
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